Findings of a trial with pemafibrate in a contemporary patient population

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
AHA 2024
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Effect of decision support system on early optimization of lipid-lowering therapy
Effect of decision support system on early optimization of lipid-lowering therapy
AHA 2024
Effect of decision support system on early optimization of lipid-lowering therapy
- Kausik Ray, MBChB, MD, MPhil
Early and sustained non-HDL-c target achievement after MI
Early and sustained non-HDL-c target achievement after MI
Hyperlipidemia
Early and sustained non-HDL-c target achievement after MI
- Jessica Schubert, MD
The remaining challenges in lowering LDL-c in patients at increased CV risk
The remaining challenges in lowering LDL-c in patients at increased CV risk
MinuteCE®
The remaining challenges in lowering LDL-c in patients at increased CV risk
0.75 program credits
- Prof. Kausik Ray
0.75 program credits